Enterovirus 71 (EV71) is causing life-threatening outbreaks in tropical Asia. In Taiwan and other tropical Asian countries, although nationwide EV71 epidemics occur cyclically, age-specific incidence rates of EV71 infections that are critical to estimate disease burden and design vaccine trials are not clear. A nationwide EV71 epidemic occurred in 2008–09 in Taiwan, which provided a unique opportunity to estimate age-specific incidence rates of EV71 infections.
We prospectively recruited 749 healthy neonates and conducted follow-ups from June 2006 to December 2009. Sera were obtained from participants at 0, 6, 12, 24, and 36 months of age for measuring EV71 neutralizing antibody titers. If the participants developed suspected enterovirus illnesses, throat swabs were collected for virus isolation.
We detected 28 EV71 infections including 20 symptomatic and 8 asymptomatic infections. Age-specific incidence rates of EV71 infection increased from 1.71 per 100 person-years at 0–6 months of age to 4.09, 5.74, and 4.97 per 100 person-years at 7–12, 13–24, and 25–36 months of age, respectively. Cumulative incidence rate was 15.15 per 100 persons by 36 months of age, respectively.
Enterovirus 71 (EV71) was first isolated in California, USA, in 1969. Since then, EV71 has been identified globally. Recently, EV71 caused several life-threatening outbreaks in young children in tropical Asia. Development of EV71 vaccines becomes national priority in several Asia countries including Taiwan. To design clinical trials of EV71 vaccines, age-specific incidence rates of EV71 infections are required to identify target populations, estimate disease burdens, select endpoints of clinical efficacy, and estimate sample size. In Taiwan, nationwide EV71 epidemics occurred every 3–4 years but age-specific incidences of EV71 infection are not available. In 2006, we initiated a prospective cohort study in northern Taiwan to recruit neonates and follow up them. In 2008–09, a nationwide EV71 epidemic occurred and we found that age-specific incidence rates of EV71 infection increased from 1.71 per 100 person-years at 0–6 months of age to 4.09, 5.74, and 4.97 per 100 person-years at 7–12, 13–24, and 25–36 months of age, respectively. The cumulative incidence rate was 15% by 36 months of age, and 29% of EV71 infections were asymptomatic in young children. These findings would be helpful to development of EV71 vaccines in Taiwan and other Asian tropical countries.
Citation: Lee M-S, Chiang P-S, Luo S-T, Huang M-L, Liou G-Y, Tsao K-C, et al. (2012) Incidence Rates of Enterovirus 71 Infections in Young Children during a Nationwide Epidemic in Taiwan, 2008–09. PLoS Negl Trop Dis 6(2): e1476. https://doi.org/10.1371/journal.pntd.0001476
Editor: Judd L. Walson, University of Washington, United States of America
Received: September 28, 2011; Accepted: December 3, 2011; Published: February 14, 2012
Copyright: © 2012 Lee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by the National Health Research Institutes, Taiwan and the National Science Council (NSC99-2321-B-002-025), Taiwan. The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The corresponding author had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Competing interests: The authors have declared that no competing interests exist.
Enterovirus 71 (EV71) was first isolated in California, USA, in 1969. Since then, EV71 has been identified globally. The clinical spectrum of EV71 infection ranges from asymptomatic infection, to mild hand-foot-mouth disease (HFMD), and severe cases with central nervous system (CNS), and cardiopulmonary involvement , . Recent studies have further demonstrated that CNS-complicated EV71 infections could cause long-term cognitive and motor deficits , . Globally, two patterns of EV71 outbreaks have been reported: small-scale outbreaks with few CNS-complicated cases and deaths, and large-scale outbreaks with frequent CNS-complicated cases and deaths . The latter pattern occurred in Bulgaria, with 44 deaths in 1975 ; in Hungary, with 45 deaths in 1978 ; in Malaysia, with 29 deaths in 1997 ; in Taiwan, with 78 deaths in 1998 ; in Singapore, with 5 deaths in 2000 ; and recently in China, with more than 100 deaths in 2007, 2008, and 2009 –. Since the 1998 epidemic, EV71 has continued to cause nationwide epidemics again in 2000–2001, 2004–2005, and 2008–2009 in Taiwan –.
No antiviral against EV71 is currently available, so development of EV71 vaccines has become a national priority in Taiwan and China, and several organizations in Asia are planning clinical trials of EV71 vaccines . To design clinical trials of EV71 vaccines, age-specific incidence rates of EV71 infections are required to identify target populations, estimate disease burdens, select endpoints of clinical efficacy, and estimate sample size. Taiwan has had a national surveillance system for severe enterovirus infections since 1998. Age-specific incidence rates of EV71-related severe infections during the 1998 epidemic have been estimated to be 27.3, 37.1, 30.0, and 23.1 per 100,000 for children aged <6, 6–11, 12–23, and 24–35 months, respectively , which are too low to be a suitable clinical endpoint. Alternatively, EV71-related mild infections such as herpangina and HFMD could be suitable clinical endpoints; but their age-specific incidence rates are not available in Taiwan. We initiated a longitudinal cohort study in 2006 to estimate age-specific incidence rates of EV71 infection in young children in northern Taiwan.
Institutional review board approval was obtained from Chang Gung Memorial Hospital (CGMH) following the Helsinki Declaration; and written informed consent was obtained from all mothers of participating infants.
Pregnant women having prenatal exams in CGMH were invited to participate in the study starting in June 2006. Sera were obtained from participating pregnant women and their children for measuring EV71 neutralizing antibody titers in the following schedule: pregnant women immediately before delivery; neonates at birth (cord blood); and infants at 6, 12, 24, and 36 months of age. About 20–30 participants were recruited every month. Parents were educated to contact study staff when their children developed suspected enterovirus illnesses (herpangina or HFMD). During enterovirus seasons, study staff actively contacted parents about suspected enterovirus illnesses by e-mail, telephone or text message. If the participating children developed suspected enterovirus illnesses, throat swabs were collected from these participating children for virus isolation. In previous studies, throat swabs were more sensitive than rectal swabs or feces for isolating EV71 viruses in acute EV71 cases . Occasionally, pediatricians also collected throat swabs from the participating children who developed non-specific febrile illness for virus isolation during enterovirus seasons. We chose CGMH as a study site because it has large obstetric and pediatric populations and serves residents from both rural and urban areas in northern Taiwan , –. In additional to the infant cohort study, clinical samples (throat swabs, rectal swabs, or stool samples) are routinely collected for virus isolation from hospitalized pediatric patients with suspected enterovirus infections (herpangina, HFMD, or non-specific febrile illness) in CGMH. Monthly distribution of EV71 isolation in pediatric inpatients the study hospital is based on the routine statistics and is anonymized. This information was used to decide EV71 seasons for data analysis. Data related to serum EV71 antibody titers in pregnant women, neonates and 6-month-old infants have been published previously  and this report focused on incidence rate of EV71 infections in the first three years of life.
Clinical and laboratory definitions
In this study, evidence of herpangina included oral ulcerations on anterior tonsillar pillars, soft palate, buccal mucosa, or uvula. Evidence of HFMD included oral ulcers on the tongue and buccal mucosa, and a vesicular rash on the hands, feet, knees, or buttocks. Nonspecific febrile illness was defined as a rectal temperature greater than 38°C without other symptoms. Laboratory evidence of EV71 infection was defined as the isolation of EV71 from a throat swab; or a ≥4-fold rise or seroconversion in EV71 neutralizing antibody titers in paired sera samples. Asymptomatic EV71 infection was defined as a seroconversion in EV71 neutralizing antibody titers in paired sera samples without display of clinical symptoms during the period of collection of paired sera.
Samples were inoculated into human embryonic fibroblast, LLC-MK2, HEp-2, and rhabdomyosarcoma cell cultures. When enteroviral cytopathic effect involved more than 50% of the cell monolayer, cells were scraped and subjected to indirect fluorescent antibody staining with enterovirus monoclonal antibodies .
Laboratory methods for measuring EV71 serum neutralizing antibody titers followed standard protocols –. Twofold serially diluted sera (1∶8–1∶512) and a virus working solution containing 100 TCID50 of EV71 strain E59-TW-2002 (B4 genotype) were mixed on 96-well microplates and incubated with rhabdomyosarcoma cells. A cytopathic effect was observed in a monitor linked with an inverted microscope after an incubation period of 4 to 5 days. The neutralization titers were read as the highest dilution that could result in a 50% reduction in the cytopathic effect. Each test sample was run simultaneously with cell control, serum control, and virus back titration. The starting dilution was 1∶8; the cutoff level of seropositivity was set at 8. For deciding serostatus (positive or negative), sera were tested only at 1∶8.
Since no EV71 infection was detected in our study cohort in 2006 and 2007 , observation time (person-months) for participants who returned for follow up during 2008 and 2009 were summed and converted to person-years to calculate age-specific incidence rates and 95% confidence interval (95% CI) based on the Poisson distribution . Cumulative incidence rates were calculated for participants who returned for follow up; and 95% CIs of cumulative incidence rates were calculated based on the binominal exact distribution. Neutralization antibody titers were log-transformed to calculate the GMT and 95% CI. The statistical association between two nominal or ordinal variables was tested by the χ2 test, Fisher's exact test, or the Mantel-Haenszel χ2 test for trend, as appropriate. All statistical analyses were performed using Microsoft Excel (Microsoft, Redmond, WA, USA) or SAS (SAS Institutes, Cary, NC, USA).
In CGMH, clinical samples are routinely collected for virus isolation from hospitalized pediatric patients with suspected enterovirus infections. From 2007 to 2009, 4691 pediatric inpatients were tested for enterovirus cultures and the enterovirus isolation rates in these three years were 14% (207/1475), 21% (420/1969), and 15% (181/1247), respectively. EV71 was isolated from 123 inpatients, including 5 cases in 2007, 104 cases in 2008, and 14 cases in 2009. Only 5 sporadic EV71 inpatients were detected in 2007, all in the middle of the year. In January 2008, EV71 inpatients began being detected again, with the numbers growing rapidly before peaking in June of that year and disappearing after July 2009 (Fig. 1). Overall, the pattern was consistent with that observed in the prospective cohort study.
Between June 2006 to June 2009, 749 neonates were recruited into the cohort study. In 2008–09, 124 herpangina and 9 HFMD cases were detected and 128 of them provided clinical samples (throat swabs or serum) for laboratory diagnosis. In addition, 20 children developing non-specific illnesses including fever, upper respiratory illness, and viral exanthema also provided clinical samples for laboratory diagnosis. Among 118 symptomatic children providing throat swabs for virus culture, 40 (34%) had enterovirus isolated and 5 were EV71. In total, 20 symptomatic EV71 infections were detected in the children's cohort study, including 5 herpangina cases, 6 HFMD cases, and 9 cases with the non-specific illnesses (Table 1). None of the EV71 cases identified in the cohort developed complications. Among the 20 symptomatic EV71 infections, all developed seroconversion and 9 of them provided throat swabs for virus culture in acute phase. In these 9 cases, EV71 and cytomegalovirus were isolated from 5 and 2 cases, respectively. Overall, the virus isolation rate was significantly lower than the seroconversion rates for detecting EV71 infections (4.2% vs. 16.7%, P<0.01, Fisher's exact test). In addition, 8 asymptomatic EV71 infections were detected by seroconversion.
Between January 2008 and December 2009, 307, 391, 294, and 66 children returned for follow up and serum collections at 6, 12, 24, and 36 months of age, respectively. Overall, the follow-up rates at 6, 12, 24 and 36 months of age were 73%, 67%, 55% and 51%, respectively. The major reason for loss of follow-up was refusal of providing blood samples. As shown in Table 2, age-specific incidence rates of EV71 infections in young children increased gradually from 1.71 per 100 person-years at 0–6 months of age to 4.09, 5.74, and 4.97 per 100 person-years at 7–12, 13–24, and 25–36 months of age, respectively. Table 3 shows the cumulative incidence rates, which increased from 0.65% (95% CI, 0.08%, 2.33%) at 6 months of age to 6.46% (95% CI, 3.94%, 9.91%) and 15.15 (95% CI, 7.51%, 26.1%) at 24 and 36 months of age, respectively.
Two children who acquired EV71 infections before 6 months of age were both asymptomatic and one of them had neutralizing antibody titer in cord blood (antibody titer 16). Among 7 children who acquired EV71 infections at 7–12 months of age, 2 were asymptomatic and 5 were symptomatic. The 2 asymptomatic cases both had neutralizing antibody titer in cord bloods and their maternal antibodies declined to undetectable level at 6 months of age. In contrast, only 2 of the 5 symptomatic cases had detectable EV71 neutralizing antibody in cord blood and their maternal antibodies also declined to undetectable level at 6 months of age. The 2 symptomatic cases with detectable maternal antibody in cord blood were infected at 7 and 9 months of age and the 3 symptomatic cases without detectable maternal antibody in cord blood were infected at 7, 8 and 9 months of age.
EV71 continues to cause disease with the potential for life-threatening infections in Asian children. Development of EV71 vaccines has become a national priority in Taiwan and China. To design clinical trials of EV71 vaccines, age-specific incidence rates of EV71 infections are required to identify target populations and select study endpoints. In this study, risk of EV71 infections greatly increased after 6 months of age during EV71 epidemics, which is consistent with national surveillance data of severe EV71 infections and decline of maternal antibody by 6 months of age –. Furthermore, the cumulative incidence rate in young children was about 15% by 36 months of age after follow-up for 2 years, which is consistent with the results of seroprevalence studies conducted after the 1998 epidemic , . The follow-up rate by 36 months of age was about 51% in our study but the major reason for loss of follow-up was refusal of providing blood samples. Meanwhile, 17 (61%) of the 28 EV71-infected children continue to return for follow-up. Overall, follow-up rates in EV71-infected and uninfected children differed slightly. Therefore, the substantial loss of follow-up in our study may not cause significant bias in calculation of incidence. However, our cohort study was conducted in northern Taiwan and more severe EV71 cases were reported in southern Taiwan than in northern Taiwan during the 2008–2009 epidemic. It should be cautious about extrapolating finding of this study to whole Taiwan. In addition, EV71 epidemics occurred every 3–4 years in the past 10 years in Taiwan, which may greatly affect the estimation of age-specific incidence rates.
In addition, in our prospective cohort 29% of EV71 infections in young children were asymptomatic, 32% had non-specific illness, and 39% developed herpangina/HFMD. In a retrospective study conducted in Taiwan in 1999, Chang et al. found that 29% of 484 EV71-seropositive children <6 years of age developed herpangina/HFMD and 71% were asymptomatic . In a prospective hospital-based case-finding study conducted in a medical center in 2001–02, 6% of 183 EV71 infections in children <18 years of age were asymptomatic, 13% developed non-specific illnesses, and 71% developed herpangina/HFMD . It is hard to compare our study with the other two studies due to differences in study designs, age groups, laboratory diagnosis, and genotypes of circulating EV71. Overall, the retrospective study could not differentiate EV71 infections with non-specific illnesses from asymptomatic EV71 infections and the prospective hospital-based case-finding study would underestimate the proportion of asymptomatic infections. Therefore, our prospective infant cohort study is more likely to reflect occurrences of EV71 infections in the community.
Due to small sample size, our prospective study could not detect any complicated EV71 infections. In the prospective hospital-based case-finding study, 21% of 183 EV71 infections in children <18 years of age developed neurological complications such as meningitis and encephalitis . Based on national severe enterovirus surveillance with virus isolation and two cross-sectional serosurveys, Lu et al. estimated that 130617 Taiwanese children aged <3 years were infected with EV71 infections in 1998 and that 273 (0.21%) of these infected children developed neurological complications . Overall, the prospective hospital-based case-finding study would overestimate the proportion of EV71 infections with neurological complications and the national surveillance data would underestimate the proportion of EV71 infections with neurological complications.
Interestingly, we found that the 2 children who acquired EV71 infections before 6 months of age were both asymptomatic and their EV71 neutralizing antibody titers at birth, 6 and 12 months of age were 16, 256 and 32, and <8, 128 and no serum collected at 12 months of age, respectively. Chang et al.  also found that children <6 months of age were more likely to develop asymptomatic EV71 infections than children >6 months of age. These observations may indicate that maternal antibody may provide protection against symptomatic EV71 infections in young infants even though EV71-specific maternal antibody may have declined to undetectable levels in these young infants.
Current standard methods for laboratory diagnosis of EV71 infections include virus isolation and serum neutralizing antibody testing. In the hospital-based case finding study, serum neutralizing antibody testing (≥4-fold rise) was more sensitive than virus isolation for detecting EV71 infections , which was consistent with the finding of our infant cohort study. However, the serum neutralizing antibody testing needs to collect paired sera, which are not always available. Several studies have found that serum IgM tests based on single clinical specimen were more sensitive than virus isolation for detecting EV71 infections but had a major drawback of high false positives, especially for patients infected with Coxsackievirus A16 , . In addition, molecular tests based on single clinical specimen were also more sensitive than virus isolation for detecting EV71 infections but had a major limitation of high cost –. Our cohort study collected serial sera to detect EV71 infections and would also be more sensitive than molecular tests based on a single clinical specimen. Overall, enterovirus surveillance systems based only on virus isolation for detecting EV71 infections would significantly underestimate disease burdens of EV71 infections –. However, after introducing vaccines, vaccinated children would possess EV71 antibodies which would confound serological diagnosis of EV71 infection so it would be necessary to detect and serotype enteroviruses using virus isolation and molecular methods. Overall, harmonized and integrated laboratory diagnosis methods are urgently needed to make national enterovirus surveillance data comparable .
Like poliomyelitis viruses, vaccination would be the most cost-effective intervention to prevent EV71-related diseases in endemic countries. In Taiwan, the target population of EV71 vaccines has been identified to be infants <6 months of age , . Our prospective infant cohort study has found that EV71-related HFMD/herpangina is a suitable endpoint of vaccine efficacy trials in Taiwan. In addition, the cumulative incidence rate of EV71 infections during an EV71 epidemic was about 15% by 36 months of age, and 29% of EV71 infections were asymptomatic in young children, that are critical for designing vaccine clinical trials. Several organizations are planning clinical trials of EV71 vaccines in Asia; and EV71 vaccines could be available in the near future . To successfully introduce EV71 vaccines in epidemic areas, each country needs to well characterize its EV71 epidemiology , . Our prospective infant cohort study would be helpful to other countries for understanding their EV71 epidemiology.
The authors thank the referring physicians and mothers of participating infants. The authors also thank Mark Swofford for manuscript review and the Taiwan Centers for Disease Control for providing virus strains.
Conceived and designed the experiments: M-SL T-YL. Performed the experiments: P-SC S-TL M-LH K-CT. Analyzed the data: M-SL G-YL. Contributed reagents/materials/analysis tools: P-SC S-TL M-LH K-CT T-YL. Wrote the paper: M-SL.
- 1. Bible JM, Pantelidis P, Chan PK, Tong CY (2007) Genetic evolution of enterovirus 71: epidemiological and pathological implications. Rev Med Virol 17: 371–379.
- 2. Schmidt NJ, Lennette EH, Ho HH (1974) An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 129: 304–309.
- 3. Huang MC, Wang SM, Hsu YW, Lin HC, Chi CY, et al. (2006) Long-term cognitive and motor deficits after enterovirus 71 brainstem encephalitis in children. Pediatrics 118: e1785–1788.
- 4. Chang LY, Huang LM, Gau SS, Wu YY, Hsia SH, et al. (2007) Neurodevelopment and cognition in children after enterovirus 71 infection. N Engl J Med 356: 1226–1234.
- 5. Shindarov LM, Chumakov MP, Voroshilova MK, Bojinov S, Vasilenko SM, et al. (1979) Epidemiological, clinical, and pathomorphological characteristics of epidemic poliomyelitis-like disease caused by enterovirus 71. J Hyg Epidemiol Microbiol Immunol 23: 284–295.
- 6. Nagy G, Takatsy S, Kukan E, Mihaly I, Domok I (1982) Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol 71: 217–227.
- 7. Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, et al. (2000) Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis 31: 678–683.
- 8. Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, et al. (1999) An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 341: 929–935.
- 9. Chan KP, Goh KT, Chong CY, Teo ES, Lau G, et al. (2003) Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis 9: 78–85.
- 10. Zhang Y, Tan XJ, Wang HY, Yan DM, Zhu SL, et al. (2009) An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J Clin Virol 44: 262–267.
- 11. World Health Organization (2008) Outbreak news. Enterovirus, China. Wkly Epidemiol Rec 83: 169–170.
- 12. Lee MS, Chang LY (2010) Development of enterovirus 71 vaccines. Expert Rev Vaccines 9: 149–156.
- 13. Lin TY, Twu SJ, Ho MS, Chang LY, Lee CY (2003) Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerg Infect Dis 9: 291–293.
- 14. Chang LY, Tsao KC, Hsia SH, Shih SR, Huang CG, et al. (2004) Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA 291: 222–227.
- 15. Chen SC, Chang HL, Yan TR, Cheng YT, Chen KT (2007) An eight-year study of epidemiologic features of enterovirus 71 infection in Taiwan. Am J Trop Med Hyg 77: 188–191.
- 16. Kung SH, Wang SF, Huang CW, Hsu CC, Liu HF, et al. (2007) Genetic and antigenic analyses of enterovirus 71 isolates in Taiwan during 1998–2005. Clin Microbiol Infect 13: 782–787.
- 17. Tseng FC, Huang HC, Chi CY, Lin TL, Liu CC, et al. (2007) Epidemiological survey of enterovirus infections occurring in Taiwan between 2000 and 2005: analysis of sentinel physician surveillance data. J Med Virol 79: 1850–1860.
- 18. Huang SC, Hsu YW, Wang HC, Huang SW, Kiang D, et al. (2008) Appearance of intratypic recombination of enterovirus 71 in Taiwan from 2002 to 2005. Virus Res 131: 250–259.
- 19. Huang YP, Lin TL, Kuo CY, Lin MW, Yao CY, et al. (2008) The circulation of subgenogroups B5 and C5 of enterovirus 71 in Taiwan from 2006 to 2007. Virus Res 137: 206–212.
- 20. Lin KH, Hwang KP, Ke GM, Wang CF, Ke LY, et al. (2006) Evolution of EV71 genogroup in Taiwan from 1998 to 2005: an emerging of subgenogroup C4 of EV71. J Med Virol 78: 254–262.
- 21. Huang SW, Hsu YW, Smith DJ, Kiang D, Tsai HP, et al. (2009) Reemergence of enterovirus 71 in 2008 in Taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008. J Clin Microbiol 47: 3653–3662.
- 22. Lee MS, Lin TY, Chiang PS, Li WC, Luo ST, et al. (2010) An investigation of epidemic enterovirus 71 infection in Taiwan, 2008: clinical, virologic, and serologic features. Pediatr Infect Dis J 29: 1030–1034.
- 23. Chang LY, King CC, Hsu KH, Ning HC, Tsao KC, et al. (2002) Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics 109: e88.
- 24. Luo ST, Chiang PS, Chao AS, Liou GY, Lin R, et al. (2009) Enterovirus 71 maternal antibodies in infants, Taiwan. Emerg Infect Dis 15: 581–584.
- 25. Tsao KC, Huang CG, Huang YL, Chen FC, Huang PN, et al. (2010) Epidemiologic features and virus isolation of enteroviruses in Northern Taiwan during 2000–2008. J Virol Methods 165: 330–332.
- 26. Huang ML, Chiang PS, Luo ST, Liou GY, Lee MS (2010) Development of a high-throughput assay for measuring serum neutralizing antibody against enterovirus 71. J Virol Methods 165: 42–45.
- 27. Greenland S, Rothman KJ (1998) Introduction to categorical statistics. In: Rothman KJ, Greenland S, editors. Modern Epidemiology. Philadelphia: Lippincott-Raven Publishers. pp. 231–252.
- 28. Lu CY, Lee CY, Kao CL, Shao WY, Lee PI, et al. (2002) Incidence and case-fatality rates resulting from the 1998 enterovirus 71 outbreak in Taiwan. J Med Virol 67: 217–223.
- 29. Tsao KC, Chan EC, Chang LY, Chang PY, Huang CG, et al. (2002) Responses of IgM for enterovirus 71 infection. J Med Virol 68: 574–580.
- 30. Wang SY, Lin TL, Chen HY, Lin TS (2004) Early and rapid detection of enterovirus 71 infection by an IgM-capture ELISA. J Virol Methods 119: 37–43.
- 31. Singh S, Chow VT, Phoon MC, Chan KP, Poh CL (2002) Direct detection of enterovirus 71 (EV71) in clinical specimens from a hand, foot, and mouth disease outbreak in Singapore by reverse transcription-PCR with universal enterovirus and EV71-specific primers. J Clin Microbiol 40: 2823–2827.
- 32. Tsao LY, Lin CY, Yu YY, Wang BT (2006) Microchip, reverse transcription-polymerase chain reaction and culture methods to detect enterovirus infection in pediatric patients. Pediatr Int 48: 5–10.
- 33. Perez-Velez CM, Anderson MS, Robinson CC, McFarland EJ, Nix WA, et al. (2007) Outbreak of neurologic enterovirus type 71 disease: a diagnostic challenge. Clin Infect Dis 45: 950–957.
- 34. Hadler SC, Cochi SL, Bilous J, Cutts FT (2004) Vaccination in developing countries. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 4th ed. Phildelphia: W. B. Saunders Co. pp. 1407–1441.
- 35. Lee MS, Walker RE, Mendelman PM (2005) Medical burden of respiratory syncytial virus and parainfluenza virus type 3 infection among US children. Implications for design of vaccine trials. Hum Vaccine 1: 6–11.